Showing results (191-200 of 229) with videos related to

Sort By:
Pageof 23
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|April 1, 2021
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumorsD Timmerman, F Planchamp, T Bourne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 2012
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up dataA Lintermans, A Laenen, B Van Calster, et al.
Gynecologic Oncology|November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12F Heitz, P Harter, E Åvall-Lundqvist, et al.
Breast Cancer Research and Treatment|July 15, 2009
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen usersA S Dieudonné, D Lambrechts, B Claes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Safety and dose modification for patients receiving niraparibJ S Berek, U A Matulonis, U Peen, et al.
British Journal of Cancer|September 15, 2011
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancerC K Lee, R J Simes, C Brown, et al.
Gynecologic Oncology|September 30, 2020
Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumorsC Landolfo, E T L Achten, J Ceusters, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2006
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)J A Green, E M J J Berns, C Coens, et al.
Journal of the National Cancer Institute|October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxelP Hoskins, I Vergote, A Cervantes, et al.
Gynecologic Oncology|May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancerI Vergote, E Van Nieuwenhuysen, A Casado, et al.
Pageof 23